莱博雷生国内有患者服用了吗？

There are already patients in China taking it. Lebrasyn is currently on the market in Taiwan and mainland China, so it can be purchased in hospitals and pharmacies in these two regions in China.

Domestic use of Lebrasant

As of March 22, 2024, Lebrasant has not completed the formal marketing approval process of the National Medical Products Administration in mainland China, that is, it has not yet been launched in mainland China. However, according to previous information, under the policy framework of "Hong Kong and Macao Medical Device Access", patients in specific areas of mainland China, such as Hong Kong, China, and Taiwan, China, have obtained the opportunity to use it through legal channels. In places such as Guangzhou United Family Hospital, reports have emerged that the first prescription for Lebrasin has been issued.

Therefore, although Leborexen has not yet been widely marketed in China, individual patients in some areas have begun to use this drug for insomnia treatment under the guidance of doctors. In actual application, the therapeutic effect of leborexan will vary according to each patient's specific condition and individual differences.

Leboreside drug introduction

Leboreside was approved by the US Food and Drug Administration (FDA) in December 2019. Clinicians can use Leboreside to treat insomnia in adults. Lebrazin belongs to a group of drugs called central nervous system (CNS) depressants, which slow down the nervous system to help patients fall asleep faster and stay asleep throughout the night.

In addition, Leborex has been shown to be safe for use in patients with mild obstructive sleep apnea (OSA). There are currently no other indications approved for the use of Lebrasin.

Libora belongs to a class of drugs called dual-receptor orexin antagonists (DORA). There are only two insomnia drugs that target orexin that are currently on the market. Lebraxant is the second one, and the first one is Suvorexan, which was launched in 2014.

Efficacy of Lebraxen in the treatment of insomnia

Lebraxen is a dual orexin receptor antagonist that inhibits orexin neurotransmission that regulates sleep-wake rhythms by competitively binding to two subtypes of orexin receptors (OX1R and OX2R). Leborex acts on the orexin neurotransmitter system and is thought to promote sleep onset, sleep maintenance, and arousal by regulating sleep-wake rhythms.

Leborexan has good efficacy in treating insomnia in adults. By weakening the arousal signal, it can shorten the time to fall asleep and extend the duration of sleep. It is used to treat difficulties in falling asleep or maintaining sleep. Compared with traditional sedative-hypnotic drugs, leborexan has less impact on sleep structure, daytime function, cognitive and memory functions, has low drug dependence and is highly safe. It can be used for chronic insomnia patients who are intolerant to traditional sedative-hypnotic drugs, especially elderly patients.

The price of Lebrasine

1. Hong Kong version: The Hong Kong version of Lebrasine comes in a 5mg tablet, and a box sells for about US$105.

2. Japanese Eisai version: The Japanese Eisai version of Lebrasin is available in 2.5 mg, 5 mg, and 10 mg tablets. It was used to treat insomnia in Japan on July 6, 2020, and the price ranges from US$77 to US$165.

Summary

Although Leborexan has not yet been launched in mainland China, there are already patients in China taking this drug and benefiting from it. Patients with insomnia can use it correctly under the guidance of a doctor.

Recommended hot articles: